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Purpose/Objective: In patients with glioblastoma (GBM), 
microscopic tumour spread can extend a substantial distance 
away from the gross tumour volume (GTV), requiring large 
clinical target volume (CTV) margins. Tumour spread is 
limited by the skull and potentially by other intracranial 
structures. We examined the volume of the CTV which could 
be avoided by editing the CTV according to these barriers. 
Materials and Methods: We used a dataset of 14 patients 
with GBM, each of which had been contoured 3 times, 
separated by at least a month, by 4 experienced Neuro-
Oncologists. The imaging data sets consisted of a co-
registered planning CT and contrast-enhanced T1 MRI. The 
majority of the patients had undergone debulking surgery 
(11); the other 3 had biopsy only. The use of multiple 
contours provided allowance for individual variation in 
contouring. The GTV was grown isotropically by 2.5 cm to 
generate the (pre-edit) CTV, which was automatically limited 
at the skull. Then, using a standardised department protocol, 
one oncologist edited the CTVs according to additional 
anatomical boundaries formed by the tentorium cerebelli and 
the falx. Key routes of spread were respected, including the 
cerebral peduncle for extension into the brain stem, the 
corpus callosum, and anterior and posterior commissures for 
trans-midline spread. The potential for spread through the 
inter-thalamic connection is uncertain, so this was also 
included as a potential route. The posterior fossa was 
excluded anatomically. Similar considerations could be 
applied to other high grade or low grade tumours.  
Results: The pre-edit CTV was reduced in all cases, but the 
extent depended on the anatomical location. The biggest 
reductions achieved by anatomical editing of the CTV were 
seen in inferiorly located tumours, where isotropic growth 
had unnecessarily included part of the posterior fossa. It 
proved difficult to achieve major reductions in superiorly 
located tumours because of the proximity of the corpus 
callosum, with associated potential routes of spread. For 
central deep-seated or superiorly located tumours, the 
percentage reduction in CTV was 3 - 5%. For more inferiorly 
placed tumours, the reduction was 9 - 23%, depending on 
how low and close to the posterior fossa the GTV was 
located. 
Conclusions: Editing of CTV according to internal anatomical 
barriers formed by the tentorium and falx is worthwhile, in 
reducing the volume of normal tissue which is treated 
unnecessarily. This is especially useful for tumours where 
isotropic CTV growth includes the posterior fossa. Newer 
Advancing imaging techniques to identify likely directions and 
extent of spread for individual patients would enhance this. 
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Purpose/Objective: To develop a new volumetric modulated 
arc therapy (VMAT) treatment strategy to deliver 
hypofractionated whole brain radiotherapy (HWBRT) 
associated with a simultaneous integrated boost (SIB) in 
patient with one or more brain metastases. The aim of the 
study is to evaluate the dosimetric feasibility of HWBRT plus 
SIB adding a hippocampal sparing. 
Materials and Methods: HWBRT prescription was 20 Gy in 5 
fractions and SIB dose on brain metastases was 40 Gy in 5 
fractions. The hippocampus anatomic definition and 
dosimetric constraints followed RTOG 0933 study. A planning 
organ at risk volume (PRV) of 5 mm margin was added 
isotropically to the hippocampal structures to allow a dose 
gradient with planning target volume (PTVWB). PTVWB was 
generated from the whole brain minus metastases PTVs 
(PTVSIB) and PRV hippocampus. All plans were evaluated in 
terms of target coverage, homogeneity index, mean and 
maximum doses to the hippocampus. Planning objectives 
were as follows: PTVWB D2%≤ 25 Gy with an acceptable 
deviation of 26.7 Gy, D98% ≥ 16.7 Gy with an acceptable 
deviation <16.7 Gy, PTVSIB D95% ≥ 38 Gy, hippocampus D100≤ 6 
Gy with an acceptable deviation 6.7 Gy and Dmax 10.7 Gy with 
an acceptable deviation 11.3 Gy and mean hippocampus dose 
of 8 Gy. 
Results: Ten patients with diagnosis of brain metastases were 
analysed. The mean number of brain metastasis was 2 (range 
1-5). Mean values for brain metastases were as follows: 
volume of PTVSIB= 5.5±5.9 cc (range 0.7-19.4 cc), dose to 95% 
of PTVSIB volume 39.9±0.3 Gy and homogeneity index 0.4±0.2 
(range 0.3-0.6). The mean dose to the 90% of PTVWB was 
19.8±0.2 Gy and the mean homogeneity index was 0.08±0.02 
(range 0.05-0.1). Mean hippocampal volume was 1.9±0.5 cc. 
Mean and maximum hippocampus doses were 7.7±0.2Gy 
(range 7.4-8 Gy) and 10.5±0.7Gy (range 9.4-11.3 Gy). Mean 
dose to 100% of the hippocampus volume (D100% ) was 6.6±0.2 
Gy (range 6.3-6.7).  
Conclusions: HWBRT plus SIB with hippocampal avoidance by 
mean of VMAT was feasible. All dosimetric parameters 
considered as planning objectives were satisfied in terms of 
target coverage and homogeneity index for PTVWBRT and 
PTVSIB. A phase II clinical trial is necessary to establish the 
clinical benefit of hippocampal sparing in patients with brain 
metastasis and treated with hypofractionated regime. 
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Purpose/Objective: This is the first study of treatment with 
hyperthermia associated with standard cancer treatment 
(Radiotherapy +/- Chemotherapy), carried out in Andalusia 
the south of Spain. 
Materials and Methods: The study’s objectives were to 
analyze the clinical benefits, response to treatment, 
treatment feasibility and comfort with hyperthermia 
associated with standard oncological treatment within the 
public health system in Andalusia. Secondary objectives 
analyze survival, quality of life, overall toxicity (general and 
specific oncological hyperthermia). The design is a case-
control study, applying hyperthermia treatment (10 sessions/ 
2-3 per week), with standard treatment of Radiotherapy, 
Chemotherapy or a combination of both, in patients with 
primary tumors or metastasis ones treated with radical or 
palliative treatments with a life expectancy of at least of 6 
months. Tumor locations are: Cervix, prostate, bladder, 
pancreas, non surgical head and neck tumors, brain tumors, 
preoperative rectal Cancer, advanced not surgical breast 
tumors, lung cancer. 
Results: We present preliminary data from 63 patients (31 
from the Juan Ramón Jiménez Hospital and 32 from the 
Carlos Haya Hospital), who received 10 sessions of high deep 
Hyperthermia, 2-3 times per week, 1 hour per session and a 
radiofrequency power between 150w and 400w according to 
the location of the tumor, associated with the standard 
cancer treatment (RT +/- CH). There are 38 men and 22 
women, with a mean age 59 (34-80), the majority were brain 
or head and neck tumors in Carlos Haya Hospital, and rectal, 
prostate an breast tumors in Hospital Juan Ramón Jimenez. 
The intention of the treatment was curative 48.3%, 
neoadyuvante 23.4% and palliative 28.3%. Concerning the 
toxicity, there has been a burning type grade I toxicity in 
36.3% of the cases and 66.6% of the patients had no toxicity. 
One patient reported pain/ pressure in the treatment area, 
grade I (in an ulcerated breast). Despite the mild toxicity 
presented the patient’s satisfaction with the treatment was 
very satisfactory in 81.2% of patients and acceptable in 
18.8%. The majority of the patients (83%) completed the 
Hyperthermia treatment as prescribed. 
Conclusions: The treatment is feasible and comfortable in 
81.2% of patients in a public environment health hospital, 
with mild toxicity in 33% of the cases and the rest without no 
toxicity. It is essential a proper selection of the cases to be 
treated with Hyperthermia to expect good results with this 
treatment. 
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Purpose/Objective: To analyse survival and patterns of 
failure of patients with glioblastoma (GBM) treated with 
radical chemo-radiotherapy in the Anglia Cancer Network. 
Materials and Methods: 205 patients treated with radical 
chemo-radiotherapy during January 2006 to March 2012 were 
identified. All patients had been treated to a dose of 60 Gy in 
30 fractions in two-phases with concomitant and adjuvant 
temozolomide. Postoperative resection cavity with residual 
tumour on T1W gadolinium-enhanced MRI scan was outlined 
(GTV) and a margin of 25 mm was added to obtain CTV50 (CTV 
receiving 50 Gy) and a margin of 15 mm was added to obtain 
CTV60. A 5 mm margin was added to CTV50 and CTV60 to define 
corresponding PTVs. 124 patients had MRI confirmed 
relapse/progression. T1W-Gd MRI data sets showing recurrent 
tumour in patients (n=34) treated at one of the Anglia Cancer 
Network Hospitals (Norfolk and Norwich University Hospital) 
were co-registered with planning CT scan to delineate 
recurrent tumour and to correlate the pattern of failure with 
the actual radiation dose delivered (Figure 1A-C). Overall 
survival was calculated using the Kaplan-Meier method. 
Results: Median follow-up of 205 patients treated with 
radical chemo-radiotherapy was 37.7 months. The median 
survival was 16.5 months (95% CI 14.7 – 18.3). The 2-year 
overall survival (OS) was 32%, 3-year OS 17%, and 5-year OS 
12%. The median OS of patients (n=34) included in the 
patterns-of-failure study was 17.7 months (95% CI: 13.4-22.1) 
and median progression-free interval was 7.8 months (95% CI: 
6.3-8.6). In 25 out of 34 patients (74%), treatment failure 
developed within a region previously irradiated to 57 Gy (D57) 
(figure 1D). In 7 patients treatment failure developed within 
D>50 (area received >50 Gy), where on average 3% of recurrent 
tumour volume received 50-57Gy and 97% received >57 Gy. In 
one patient, 54% of recurrent tumour volume received >50 Gy 
while, 42% received <30 Gy. One patient had a recurrent 
tumour outside D30 (area received 30 Gy). Further analysis of 




Conclusions: The survival of patients in this series is similar 
to that reported in the Stupp study1. Based on this small 
cohort, there may be at least three different patterns of 
failure: tumour recurrence within the high-dose radiotherapy 
(>57 Gy) region continues to be the predominant pattern 
(74%). In >20% of patients, treatment failure developed at 
the edge of the high-dose radiotherapy region (50-57Gy) 
suggesting the need for incorporation of better imaging 
